US FDA Panel Votes 17-6 Obesity Drugs Without Initial Signal Of Cardiovascular Harm Should Still Be Required To Rule Out Excess Cardiovascular Risk With Clinical Trial Or Meta-Analysis -Reuters
Eddie Staley